Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative dieses associated with abnormal accumulation of protein tau.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative dieses associated with abnormal accumulation of protein tau.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The present disclosure generally relates to genetic engineering of bacteria. More particularly, the present disclosure describes genetic engineering of E. coli to create mutant O-antigen ligase, as well as novel lipopolysaccharide molecules resulting from that genetic engineering. Methods for using those novel molecules are also described.

Abstract: The subject invention pertains to myricanol derivatives, therapeutic compositions, and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau.

Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Abstract: The subject invention provides a myricanol compound that is in predominant form of (+)-?R,11S-myricanol as compared to (?)-?S,11R-myricanol. In one embodiment, the (+)-?R,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (?)-?S,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Abstract: A support stand including three upright, cylindrical lower support legs, each leg having a foot extending perpendicularly of the lower end of the leg. The stand further includes two vertically spaced connecting blocks having aligned linearly arranged apertures for receiving the legs, with the upper block mounted over the upper ends of the legs. The two outer legs are rotatably mounted in the blocks to permit the outer legs to be rotated to move the respective feet between a storage position, with the feet substantially aligned and extending perpendicularly of the blocks, and the support position with the feet splayed apart. An upright, cylindrical upper support leg is provided for mounting a support for a book, or piece of equipment such as a microphone and is telescopicaly received within the center leg.